# Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

> **NCT05838560** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 40 (estimated)

## Conditions studied

- Schizophrenia
- Treatment Resistant Depression
- Aging, Premature

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** quercetin

## Key facts

- **NCT ID:** NCT05838560
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- UConn Health

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05838560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05838560, "Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05838560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*